Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world.
It is a $20.9B healthcare company. Revenue grew 8.4% over the last year, it keeps 13¢ of every dollar of sales as profit, and its net debt equals ~1.8 years of free cash flow. It trades at 26.0× earnings — near the lowest of its own history.
- Website
- steris.com
- Location
- Dublin, L2
- Employees
- 17 937
- Sector
- Healthcare
- Founded
- 1985
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong valuation, health and quality.
Valuation77
- P/E vs own history3th pct · 25/25
- FCF yield4.4% · 12/25
- P/S3.5x · 20/25
- EV/EBITDA13.7x · 20/25
Growth74
- Revenue CAGR6.7% · 12/25
- Net income CAGR33.8% · 25/25
- EPS CAGR ~5Y8.6% · 12/25
- Fwd implied growth45.2% · 25/25
Profitability64
- ROIC8.8% · 12/25
- ROE11.3% · 12/25
- Net margin13.3% · 20/25
- Operating margin18.9% · 20/25
Health80
- Altman Z4.34 · 25/25
- Current ratio1.91 · 18/25
- Interest coverage21.6x · 25/25
- Net cash / debtD/A 15% · 12/25
Quality100
- Piotroski F8/9 · 25/25
- Beneish M-2.56 · 25/25
- FCF conversion115% · 25/25
- Margin stabilityσ 3.8% · 25/25
Moat57
- ROIC >12% years0/8 yrs · 0/25
- Median gross margin43.6% · 20/25
- FCF-positive years8/8 yrs · 25/25
- Worst-year net marginworst 2.4% · 12/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- FY2026FinancialBest year on record$782M net income
- 2021AcquisitionSteris acquired Cantel Medical Corporation a provider of infection prevention products and services to…
- 2020AcquisitionSteris acquired Key Surgical, a leading global provider of sterile processing, operating room
- FY2019FinancialProfitable every year on record8 consecutive profitable years in our data
- FY2019FinancialRevenue already above $1B$2.78B in first reported year
- FY2019FinancialPositive free cash flow every year since8-year streak
- 2014AcquisitionSteris executed a tax inversion from the United States to the United Kingdom, via an offer made to…
- 2014ProductThe tax inversion was notable as it was the first US inversion post the new rules introduced by the Obama…
- 2012AcquisitionSteris acquired US Endoscopy for $270 million
- 1985FoundedSteris was founded in August 1985 in Ohio, under the name "Innovative Medical Technologies"
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (44.4%)
- Strong cash conversion — FCF is 15.3% of revenue
- Could repay net debt from ~1.7 years of free cash flow
- Interest covered 21.6× by operating earnings
- Piotroski F-Score 8/9 — fundamentally strong checklist
Watch-outs
Nothing stands out as a concern in the available data.
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+8.4% YoY
- Profitable — makes more than it spends$805M TTM
- Profit growing — earnings are higher than last year+95.1% YoY
- Generates cash — cash left after running and investing$926M TTM
- Debt under control — could handle its obligations~1.8y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$20.9B market cap
- Not printing shares — share count not ballooning — you keep your slice+30.2% shares over ~5y
- Proven track record — years of profitability behind it8/8 profitable years
- Financially stable — balance sheet not near distressAltman Z 4.3 — safe
- Pays a dividend — returns cash to shareholdersyield 1.18%
- Valuation not extreme — price not wildly above earningsP/E 26.0
Peer comparisonSTERIS plc vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| STE this company | $20.9B | 26.0 | +8.4% | 13.3% | Strong |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: STE vs LLY · STE vs JNJ · STE vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2019–FY2026. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/STE
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of STE on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $214.40 · market cap $20.9B.